Use of MALDI-TOF mass spectrometry to detect nosocomial outbreaks of Serratia marcescens and Citrobacter freundii.
Anti-Bacterial Agents
/ pharmacology
Bacterial Proteins
/ biosynthesis
Bacterial Typing Techniques
/ methods
Citrobacter freundii
/ classification
Cross Infection
/ epidemiology
Disease Outbreaks
Enterobacteriaceae Infections
/ epidemiology
Germany
/ epidemiology
Humans
Intensive Care Units, Neonatal
Microbial Sensitivity Tests
Serratia marcescens
/ classification
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Whole Genome Sequencing
beta-Lactamases
/ biosynthesis
Citrobacter freundii
MALDI-TOF
Serratia marcescens
Typing
Whole genome sequencing
Journal
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297
Informations de publication
Date de publication:
Mar 2019
Mar 2019
Historique:
received:
28
11
2018
accepted:
26
12
2018
pubmed:
27
1
2019
medline:
13
9
2019
entrez:
26
1
2019
Statut:
ppublish
Résumé
MALDI-TOF mass spectrometry (MS) may be used as a rapid typing method for nosocomial pathogens. Here, we evaluated MALDI-TOF MS for discrimination of hospital outbreak-related clusters of Serratia marcescens and carbapenemase-producing Citrobacter freundii. Thirty-three S. marcescens isolates collected from neonatal intensive care unit (NICU) patients, and 23 C. freundii isolates including VIM-positive isolates from a hospital colonization outbreak were measured by Vitek MS. Consensus spectra of each isolate were clustered using SARAMIS software. Genotyping was performed by whole-genome sequencing (WGS). First, a set of 21 S. marcescens isolates from 2014 with seven genotypes including three monoclonal clusters was used for the evaluation of MALDI-TOF typing. MS clustering was largely in agreement with genotyping results when the similarity cut-off for clonal identity was set on 90%. MALDI-TOF cluster analysis was then investigated for the surveillance of S. marcescens in the NICU in 2017 and demonstrated the introduction of new strains into the hospital and nosocomial transmissions. MS analysis of the C. freundii outbreak in 2016 revealed a monoclonal cluster of VIM-positive isolates and the separation of epidemiologically non-related VIM-positive and negative isolates. Two additional VIM-positive Citrobacter isolates from food samples were closely related to the large monoclonal cluster. WGS confirmed the MS results. MALDI-TOF MS may be used as a first-line typing tool for S. marcescens and C. freundii to detect transmission events in the hospital because isolates of an identical WGS type were grouped into the same MS cluster.
Identifiants
pubmed: 30680577
doi: 10.1007/s10096-018-03462-2
pii: 10.1007/s10096-018-03462-2
doi:
Substances chimiques
Anti-Bacterial Agents
0
Bacterial Proteins
0
beta-Lactamases
EC 3.5.2.6
carbapenemase
EC 3.5.2.6
Types de publication
Comparative Study
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
581-591Subventions
Organisme : Bundesministerium f?r Bildung und Forschung
ID : 13N13890
Références
J Clin Microbiol. 2006 Jul;44(7):2524-32
pubmed: 16825375
Clin Microbiol Infect. 2007 Oct;13 Suppl 3:1-46
pubmed: 17716294
BMC Genomics. 2011 Aug 08;12:402
pubmed: 21824423
Eur J Clin Microbiol Infect Dis. 2012 Dec;31(12):3341-50
pubmed: 22843295
Mass Spectrom Rev. 2013 May-Jun;32(3):188-217
pubmed: 22996584
Euro Surveill. 2013 Jan 24;18(4):20380
pubmed: 23369389
Euro Surveill. 2013 Jan 24;18(4):20383
pubmed: 23369394
Int J Infect Dis. 2013 Sep;17(9):e714-7
pubmed: 23528638
J Hosp Infect. 2014 Jan;86(1):57-63
pubmed: 24332914
Front Microbiol. 2014 Mar 06;5:81
pubmed: 24639671
Infection. 2014 Oct;42(5):891-8
pubmed: 25015432
J Clin Microbiol. 2015 Mar;53(3):760-5
pubmed: 25056329
Diagn Microbiol Infect Dis. 2014 Dec;80(4):267-71
pubmed: 25266674
PLoS One. 2015 Apr 10;10(4):e0120624
pubmed: 25860943
Antimicrob Agents Chemother. 2015 Oct;59(10):6477-83
pubmed: 26239991
Eur J Clin Microbiol Infect Dis. 2016 May;35(5):829-38
pubmed: 26922068
J Clin Microbiol. 2016 Sep;54(9):2391-4
pubmed: 27358465
Infection. 2016 Dec;44(6):739-746
pubmed: 27401691
J Antimicrob Chemother. 2016 Nov;71(11):3117-3124
pubmed: 27494919
J Clin Microbiol. 2016 Dec;54(12):2874-2881
pubmed: 27558178
J Clin Microbiol. 2016 Dec;54(12):2919-2927
pubmed: 27629900
PLoS One. 2016 Oct 31;11(10):e0164260
pubmed: 27798637
Eur J Clin Microbiol Infect Dis. 2017 Feb;36(2):379-386
pubmed: 27812805
J Clin Microbiol. 2017 Mar;55(3):908-913
pubmed: 28053217
Trends Microbiol. 2017 Jun;25(6):447-455
pubmed: 28094091
Genome Res. 2017 May;27(5):722-736
pubmed: 28298431
J Infect Dis. 2017 Feb 15;215(suppl_1):S28-S36
pubmed: 28375512
Microb Genom. 2017 Sep 14;3(10):e000132
pubmed: 29177090
Clin Infect Dis. 2018 Jun 18;67(1):58-64
pubmed: 29346622
J Clin Microbiol. 2018 Aug 27;56(9):
pubmed: 29899005